Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions
Posted: February 6, 2023 at 12:50 am
Data from a First-in-Human feasibility trial to treat glaucoma continues to demonstrate a 45% reduction in mean intraocular pressure at 6 months. Malik Y. Kahook, M.D. presented the compelling 6-month results during the New Horizons Forum at the Glaucoma 360 meeting in San Francisco. Data from a First-in-Human feasibility trial to treat glaucoma continues to demonstrate a 45% reduction in mean intraocular pressure at 6 months. Malik Y. Kahook, M.D. presented the compelling 6-month results during the New Horizons Forum at the Glaucoma 360 meeting in San Francisco.
Posted in Global News Feed
Comments Off on SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions
Trading in Novo Nordisk shares by board members, executives and associated persons
Posted: February 6, 2023 at 12:50 am
Bagsværd, Denmark, 3 February 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Read more:
Trading in Novo Nordisk shares by board members, executives and associated persons
Posted in Global News Feed
Comments Off on Trading in Novo Nordisk shares by board members, executives and associated persons
VALNEVA Declaration of shares and voting rights – January 31, 2023
Posted: February 6, 2023 at 12:50 am
VALNEVA
Read the original:
VALNEVA Declaration of shares and voting rights - January 31, 2023
Posted in Global News Feed
Comments Off on VALNEVA Declaration of shares and voting rights – January 31, 2023
Oxurion Receives Transparency Notifications from Negma Group
Posted: February 6, 2023 at 12:50 am
Oxurion Receives Transparency Notifications from Negma Group
More here:
Oxurion Receives Transparency Notifications from Negma Group
Posted in Global News Feed
Comments Off on Oxurion Receives Transparency Notifications from Negma Group
SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System
Posted: February 6, 2023 at 12:50 am
CLEVELAND, Feb. 03, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or chronic pain, announced it has obtained clearance from the U.S. Food and Drug Administration (FDA) for expanded labeling, which increases the intended patient population of the SPRINT® PNS System, along with new advances to enhance and simplify the SPRINT PNS System’s lead securement mechanism.
Go here to read the rest:
SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System
Posted in Global News Feed
Comments Off on SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Posted: February 6, 2023 at 12:50 am
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 1, 2023 (the “Grant Date”), ORIC granted a total of 35,596 non-qualified stock options and 5,948 restricted stock units to three new non-executive employees who began their employment with ORIC in January 2023.
More here:
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Posted in Global News Feed
Comments Off on ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
Posted: February 6, 2023 at 12:50 am
Basel, February 4, 2023 – Novartis announced today that The Lancet has published long-term data from the pivotal SUNSHINE and SUNRISE trials evaluating Cosentyx® (secukinumab) in moderate-to-severe hidradenitis suppurativa (HS)1. In two of the largest Phase III trials conducted in HS, Cosentyx treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% of patients achieving a HS Clinical Response (HiSCR) measure at Week 521.
Posted in Global News Feed
Comments Off on Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
Bioasis Announces AGM Results and Provides Update on Financial Position
Posted: February 6, 2023 at 12:50 am
NEW HAVEN, Conn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, is pleased to announce that all resolutions were passed by the requisite majority at its annual general meeting (the “Meeting”) held earlier today.
Follow this link:
Bioasis Announces AGM Results and Provides Update on Financial Position
Posted in Global News Feed
Comments Off on Bioasis Announces AGM Results and Provides Update on Financial Position
City of Vacaville Introduces Next Generation to Biotechnology and Advanced Manufacturing
Posted: February 6, 2023 at 12:50 am
Vacaville high school students explore local career opportunities to honor National Career Technical Education Month Vacaville high school students explore local career opportunities to honor National Career Technical Education Month
Go here to read the rest:
City of Vacaville Introduces Next Generation to Biotechnology and Advanced Manufacturing
Posted in Global News Feed
Comments Off on City of Vacaville Introduces Next Generation to Biotechnology and Advanced Manufacturing
Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer &…
Posted: February 6, 2023 at 12:50 am
SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today distributed dividend confirmation statements to 146 brokerage firms regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) held by Sorrento. These statements, which contain the account numbers and amount of Scilex dividend shares, were previously mailed out by Continental Stock Transfer & Trust Company.
Posted in Global News Feed
Comments Off on Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer &…